Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial
Coordinated germline and tumor panel testing was feasible and revealed P/LP CPG variants in 6.3% of the Pediatric MATCH cohort. Tumor variant fraction, germline association of CPG with tumor type, and adult-oriented guidelines were not predictive of germline status, emphasizing the need for systematic germline follow-up after tumor genomic testing for pediatric patients.
Authors
- Gregory J. Tsongalis (ORCID: https://orcid.org/0000-0002-0792-3196)
- Steven Joffe (ORCID: https://orcid.org/0000-0002-0667-7384)
- Mary V. Relling (ORCID: https://orcid.org/0000-0002-3720-9591)
- Cynthia Winter
- Jin Piao (ORCID: https://orcid.org/0000-0003-0516-6280)
- Lauren Saguilig
- Jaclyn A. Biegel (ORCID: https://orcid.org/0000-0001-9270-6411)
- Conrad V. Fernandez (ORCID: https://orcid.org/0000-0002-0746-8306)
- Sharon E. Plon (ORCID: https://orcid.org/0000-0002-9626-0936)
- David R. Patton (ORCID: https://orcid.org/0000-0003-3855-0166)
- George Miles (ORCID: https://orcid.org/0000-0002-1554-3214)
- D. Williams Parsons (ORCID: https://orcid.org/0000-0002-8775-3501)
- Mark J. Routbort (ORCID: https://orcid.org/0000-0003-4860-261X)
- Nita L. Seibel (ORCID: https://orcid.org/0000-0001-6259-7955)
- Brenda J. Weigel (ORCID: https://orcid.org/0000-0003-1080-1402)
- Elizabeth Fox (ORCID: https://orcid.org/0000-0002-9998-5326)
- Nilsa C. Ramirez (ORCID: https://orcid.org/0000-0002-9945-9449)
- Katherine A. Janeway (ORCID: https://orcid.org/0000-0001-6000-3594)
- Sarah Scollon (ORCID: https://orcid.org/0000-0003-2017-0245)
- Jeffrey S. Abrams (ORCID: https://orcid.org/0000-0001-7787-7730)
- Shashikant Kulkarni (ORCID: https://orcid.org/0000-0002-9349-0787)
- Douglas R. Stewart (ORCID: https://orcid.org/0000-0001-8193-1488)
- Margaret Mooney (ORCID: https://orcid.org/0000-0002-6998-8331)
- Todd A. Alonzo (ORCID: https://orcid.org/0000-0002-6772-6581)
- Brent D. Coffey (ORCID: https://orcid.org/0009-0009-2047-5699)
- James V. Tricoli (ORCID: https://orcid.org/0000-0003-3975-8516)
- Stacey L. Berg (ORCID: https://orcid.org/0000-0003-2832-9994)
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Douglas S. Hawkins (ORCID: https://orcid.org/0000-0003-3602-1375)
- Jennifer A. Oberg (ORCID: https://orcid.org/0000-0002-9135-3391)
- David M. Malkin (ORCID: https://orcid.org/0000-0001-5752-9763)
- Lisa Diller
- Lisa Schwartz
- Swapnil Kulkarni (ORCID: https://orcid.org/0009-0004-9825-9164)
- J. D. Schiffman
Institutions
- Dartmouth College (US)
- University of Southern California (US)
- Dartmouth–Hitchcock Medical Center (US)
- Seattle Children's Hospital (US)
- National Institutes of Health (US)
- University of Minnesota (US)
- St. Jude Children's Research Hospital (US)
- Nationwide Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Children's Hospital of Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- University of Washington (US)
- Center for Information Technology (US)
- Dana-Farber Cancer Institute (US)
- Children's Oncology Group (US)
- University of Minnesota Medical Center (US)
- National Cancer Institute (US)
- Children's Cancer Center (US)
- Minnesota Oncology (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/po-25-00742
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00